12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

laViv azficel-T regulatory update

FDA accepted for review a response from Fibrocell to a 2009 complete response letter for laViv azficel-T...

Read the full 62 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >